Selexipag is a selective, non-prostanoid prostacyclin receptor (IP receptor) agonist primarily indicated for the treatment of pulmonary arterial hypertension to improve pulmonary blood flow and reduce… Read more









![Chemical structure of 2-{4-[N-(5,6-Diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}acetic Acid tert-Butyl Ester](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F475084-96-9-2-4-N-56-Diphenylpyrazin-2-yl-N-isopropylaminobutyloxyacetic-Acid-tert-Butyl-Ester.png&w=3840&q=75)






































Selexipag is a selective, non-prostanoid prostacyclin receptor (IP receptor) agonist primarily indicated for the treatment of pulmonary arterial hypertension to improve pulmonary blood flow and reduce vascular resistance. This category provides comprehensive analytical support for researchers and pharmaceutical laboratories, offering a range of high-quality Selexipag reference standards, its active metabolite, and a diverse array of identified impurities and degradation products. These materials are essential for rigorous quality control, enabling accurate impurity profiling and the validation of analytical methods during development and batch release testing. Furthermore, the inclusion of stable isotope labelled compounds facilitates precise quantification in complex biological matrices via mass spectrometry-based assays. By utilizing these well-characterized standards, laboratories can ensure consistent product quality, meet regulatory requirements for safety and efficacy, and maintain reliable analytical performance throughout the pharmaceutical lifecycle.